Aims and Scope

Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

Rapid Publication

The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies.

Personal Service

The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts.

Enhanced Digital Features

Diabetes Therapy is able to publish a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Every paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the key points of the content to a wider readership. Articles also have the option to include various other types of enhanced digital features including, but not limited to, slide sets, videos and video abstracts, infographics, podcasts and animations. All enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. They can either be submitted at the same time as the manuscript or can be submitted retrospectively, and there is no additional cost to publish these features.

By having a choice of media not limited to text, figures and tables alone, readers may receive information more efficiently, whilst being reassured that the content has undergone the same rigorous peer review as the original article. Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research.

For questions relating specifically to enhanced digital features, please contact adisdigitalfeatures@springer.com.

Plain Language Summaries

Articles published in Diabetes Therapy can be accompanied by Plain Language Summaries to assist non-experts in understanding important medical advances. These summaries can help the content to reach a broader audience thus supporting the effective dissemination of research.

Peer Review Process

Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.

At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.

Publication Fees

Upon acceptance of an article, authors will be required to pay the Rapid Service Fee of €5250/$6000 (all articles published open access). The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without the Rapid Service Fee (pending peer review) for every three reviews completed per calendar year.

Preprints

We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please follow the link for further information on preprint sharing:
https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550

Copyright

Diabetes Therapy's is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.

Contact

For more information about the journal, including pre-submission enquiries, please contact victoria.glasson@springer.com

Co-Editors-in-Chief
  • Marc Evans
Co-Editor-in-Chief
  • Fernando Ovalle
Publishing model
Open Access. Learn about OA at Springer
Impact
Impact factor: 2.827 (2018)
Five year impact factor: 2.872 (2018)
Speed
Submission to first decision: 17 days
Usage
Downloads: 428,186 (2018)

Articles

About this journal

Electronic ISSN
1869-6961
Print ISSN
1869-6953
Abstracted and indexed in
  1. Chemical Abstracts Service (CAS)
  2. Chinese Academy of Sciences (CAS) - GoOA
  3. DOAJ
  4. EBSCO Academic Search
  5. EBSCO Discovery Service
  6. EMBASE
  7. Google Scholar
  8. Institute of Scientific and Technical Information of China
  9. Journal Citation Reports/Science Edition
  10. Naver
  11. OCLC WorldCat Discovery Service
  12. ProQuest Central
  13. ProQuest Consumer Health
  14. ProQuest Health & Medical Collection
  15. ProQuest Health Research Premium Collection
  16. ProQuest Nursing & Allied Health Database
  17. ProQuest Pharma Collection
  18. ProQuest Public Health Database
  19. ProQuest-ExLibris Primo
  20. ProQuest-ExLibris Summon
  21. PubMedCentral
  22. Reaxys
  23. SCImago
  24. SCOPUS
  25. Science Citation Index Expanded (SciSearch)
  26. Semantic Scholar
Copyright information